Theravance Biopharma Inc

TBPH

Market Cap$466.88M

Close$

Compare Theravance Biopharma

	P/E Ratio	Dividends	Return on Equity	Price-to-Sales	Debt-to-Equity
Theravance Biopharma Inc	-8.5	0%	-22%	9.6	0.2
Market Avg	54.3	1.27%	32%	-	1.3
Healthcare Avg	39.1	1.36%	17%	7.2	1.3

$21.00

Target Price by Analysts

118.8% upsideTheravance Biopharma Target Price Details

$10.75

Current Fair Value

12% upside

Undervalued by 12% based on the discounted cash flow analysis.

Share Statistics

Market cap	$466.88 Million
Enterprise Value	$414.81 Million
Dividend Yield	$0.0 (0.0%)
Earnings per Share	$-1.0
Beta	0.47
Outstanding Shares	48,633,224
Avg 30 Day Volume	423,033

Return

Return on Equity	-
Return on Assets	-
Return on Invested Capital	-

Valuation & Multiples

P/E Ratio	-8.46
PEG	17.92
Price to Sales	9.6
Price to Book Ratio	2.4
Enterprise Value to Revenue	6.74
Enterprise Value to EBIT	-10.08
Enterprise Value to Net Income	-10
Total Debt to Enterprise	0.12
Debt to Equity	0.23

Revenue Sources

No data

ESG Score

No data

About Theravance Biopharma Inc

CEO: Rick Winningham